These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 5071956)

  • 1. Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver.
    Cameron DP; Burger HG; Catt KJ; Gordon E; Watts JM
    Metabolism; 1972 Oct; 21(10):895-904. PubMed ID: 5071956
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic clearance of human growth hormone.
    Taylor AL; Lipman RL; Salam A; Mintz DH
    J Clin Endocrinol Metab; 1972 Feb; 34(2):395-9. PubMed ID: 5059767
    [No Abstract]   [Full Text] [Related]  

  • 3. Calcitonin clearance in the pig and in the isolated perfused pig liver.
    Greenberg PB; Martin TJ; Melick RA; Jablonski P; Watts JM
    J Endocrinol; 1972 Jul; 54(1):125-35. PubMed ID: 4339982
    [No Abstract]   [Full Text] [Related]  

  • 4. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 5. The fate of radioiodinated sheep-growth hormone in intact and nephrectomized sheep.
    Wallace AL; Stacy BD; Thorburn GD
    Pflugers Arch; 1972; 331(1):25-37. PubMed ID: 4336746
    [No Abstract]   [Full Text] [Related]  

  • 6. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure.
    Kawai S; Ichikawa Y; Homma M
    J Clin Endocrinol Metab; 1985 May; 60(5):848-54. PubMed ID: 3980669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the metabolic clearance rate, apparent distribution space and plasma half-disappearance time of unlabelled human growth hormone in normal subjects and in patients with liver disease, renal disease, thyroid disease and diabetes mellitus.
    Owens D; Srivastava MC; Tompkins CV; Nabarro JD; Sönksen PH
    Eur J Clin Invest; 1973 Jul; 3(4):284-94. PubMed ID: 4760050
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for an erythropoietin-stimulating factor in patients with renal and hepatic disease.
    Naughton BA; Liu P; Naughton GK; Gordon AS
    Acta Haematol; 1983; 69(3):171-9. PubMed ID: 6404100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of distribution in the metabolism of growth hormone in man.
    Srivastava MC; Owens D; Tompkins CV; Sönksen PH; Nabarro JD
    Biochem J; 1971 Dec; 125(3):64P-65P. PubMed ID: 5145877
    [No Abstract]   [Full Text] [Related]  

  • 11. [Aspects of water-electrolyte metabolism studied with muscle needle-biopsy. Findings in cardiac insufficiency, hepatic cirrhosis, diabetes mellitus and chronic renal insufficiency].
    Ossi E; Mioni G; D'Angelo A; Lupo A; Valvo E; Maschio G
    G Clin Med; 1974 Feb; 55(2):131-44. PubMed ID: 4419276
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome.
    Moore K; Ward PS; Taylor GW; Williams R
    Gastroenterology; 1991 Apr; 100(4):1069-77. PubMed ID: 2001805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal excretion of sulphadimidine in normal and uraemic subjects.
    Fischer E
    Lancet; 1972 Jul; 2(7770):210-2. PubMed ID: 4114211
    [No Abstract]   [Full Text] [Related]  

  • 14. Human pancreatic polypeptide in chronic renal failure and cirrhosis of the liver: role of kidneys and liver in pancreatic polypeptide metabolism.
    Boden G; Master RW; Owen OE; Rudnick MR
    J Clin Endocrinol Metab; 1980 Sep; 51(3):573-8. PubMed ID: 7410534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clevage of exogenous lipids in patients with chronic hepatic disease].
    Shaternikov VA; Loranskaia TI; Beiul EA; Savchuk LA
    Vopr Pitan; 1969; 28(2):11-6. PubMed ID: 5367242
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of the kidney in the clearance of exogenous growth hormone in the rat.
    Nail BS
    J Physiol; 1969 Mar; 201(1):37P. PubMed ID: 5773568
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of trapidil in patients with chronic liver disease.
    Berndt A; Looby M; Pönicke K; Zipprich B; Weiss M
    J Clin Pharmacol; 1996 Oct; 36(10):897-902. PubMed ID: 8930776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatic and renal elimation of bromsulphalein in chronic hepatitis, post-inflammatory cirrhosis and obstructive jaundice].
    Babiuch L
    Przegl Epidemiol; 1975; 29(2):159-67. PubMed ID: 1144806
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of atracurium and its metabolites.
    Ward S; Weatherley BC
    Br J Anaesth; 1986; 58 Suppl 1():6S-10S. PubMed ID: 3754756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labeled insulin catabolism in chronic renal failure and in the anephric state.
    Corvilain J; Brauman H; Delcroix C; Toussaint C; Vereerstraeten P; Franckson JR
    Diabetes; 1971 Jul; 20(7):467-75. PubMed ID: 5556283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.